Valneva SE (NASDAQ:VALN) Short Interest Down 34.6% in January

Valneva SE (NASDAQ:VALN) saw a large drop in short interest in January. As of January 15th, there was short interest totalling 15,900 shares, a drop of 34.6% from the December 31st total of 24,300 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average trading volume of 38,300 shares, the days-to-cover ratio is currently 0.4 days.

Valneva Price Performance

Shares of NASDAQ VALN opened at $5.69 on Friday. Valneva has a fifty-two week low of $3.62 and a fifty-two week high of $9.50. The stock has a market capitalization of $461.96 million, a price-to-earnings ratio of -43.73 and a beta of 1.93. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The business has a 50-day moving average of $4.32 and a 200-day moving average of $5.72.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Valneva in a research report on Friday.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Valneva stock. ABC Arbitrage SA bought a new position in shares of Valneva SE (NASDAQ:VALN) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 19,244 shares of the company’s stock, valued at approximately $84,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.